EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts

Rachel M Hendricks iD, Jung Kim iD, Jeremy S Haley iD, Mark Louie Ramos, Uyenlinh L Mirshahi, David J Carey, Douglas R Stewart iD, Lisa J McReynolds iD

Leukemia · 2025-02 · 39 (2) · 400-411

DOI: 10.1038/s41375-024-02436-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, online erschienen am 06.11.2024. Verfasst von Rachel M Hendricks und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Germ-Line Mutation, Penetrance, Myeloproliferative Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Div…, Geisinger Health System Foundation, Regeneron Pharmaceuticals (Regeneron Pharmaceuticals, Inc.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is estimated that 10% of individuals with a myeloid malignancy carry a germline susceptibility. Using the genome-first approach, in which individuals were ascertained on genotype alone, rather than clinical phenotype, we quantified the prevalence and penetrance of pathogenic germline variants in eight myeloid malignancy predisposition (gMMP) genes. ANKRD26 , CEBPA, DDX41, MECOM, SRP72, ETV6, RUNX1 and GATA2 , were analyzed from the Geisinger MyCode DiscovEHR ( n = 170,503) and the United Kingdom Biobank (UKBB, n = 469,595). We identified a high risk of myeloid malignancies (MM) (odds ratio[OR] all genes: DiscovEHR, 4.6 [95% confidential interval (CI) 2.1–9.7], p < 0.0001; UKBB, 6.0 [95% CI 4.3–8.2], p = 3.1 × 10 -27 ), and decreased overall survival (hazard ratio [HR] DiscovEHR, 1.8 [95% CI 1.3–2.6], p = 0.00049; UKBB, 1.4 [95% CI 1.2–1.8], p = 8.4 × 10 -5 ) amongst heterozygotes. Pathogenic DDX41 variants were the most commonly identified, and in UKBB showed a significantly increased risk of MM (OR 5.7 [95% CI 3.9–8.3], p = 6.0 × 10 -20 ) and increased all-cause mortality (HR 1.35 [95% CI 1.1–1.7], p = 0.0063). Through a genome-first approach, this study genetically ascertained individuals with a gMMP and determined their MM risk and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Predisposition to DiseaseGerm-Line MutationPenetranceMyeloproliferative DisordersHumansMaleFemaleMiddle AgedAgedCohort StudiesPrevalenceAdultUnited Kingdom

Autor:innen und Institutionen

  • Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Department of Genomic Health, Weis Center for Research, Geisinger Medical Center, Danville, PA, USA.
  • Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. lisa.mcreynolds@nih.gov.

ORCID-Profile: Rachel M Hendricks, Jung Kim, Jeremy S Haley, Douglas R Stewart, Lisa J McReynolds

Förderung

  • U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Div…
  • Geisinger Health System Foundation
  • Regeneron Pharmaceuticals (Regeneron Pharmaceuticals, Inc.)
  • U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute

Zitieren

APA

Hendricks, R. M., Kim, J., Haley, J. S., Ramos, M. L., Mirshahi, U. L., Carey, D. J., Stewart, D. R., & McReynolds, L. J. (2025). Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts. Leukemia, 39(2), 400-411. https://doi.org/10.1038/s41375-024-02436-y

Vancouver

Hendricks RM, Kim J, Haley JS, Ramos ML, Mirshahi UL, Carey DJ, et al. Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts. Leukemia. 2025;39(2):400-411. doi:10.1038/s41375-024-02436-y

BibTeX
@article{Hendricks2025,
  author = {Hendricks, Rachel M and Kim, Jung and Haley, Jeremy S and Ramos, Mark Louie and Mirshahi, Uyenlinh L and Carey, David J and Stewart, Douglas R and McReynolds, Lisa J},
  title = {Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts},
  journal = {Leukemia},
  year = {2025},
  volume = {39},
  number = {2},
  pages = {400--411},
  doi = {10.1038/s41375-024-02436-y}
}
Kostenlos starten →